Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,913,722
  • Shares Outstanding, K 1,028,111
  • Annual Sales, $ 113,290 K
  • Annual Income, $ -351,400 K
  • EBIT $ -256 M
  • EBITDA $ -241 M
  • 60-Month Beta -0.03
  • Price/Sales 81.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 117.61% (-3.02%)
  • Historical Volatility 151.37%
  • IV Percentile 76%
  • IV Rank 41.28%
  • IV High 192.15% on 04/17/25
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 4) 0.85 (10.06%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 28,597
  • Volume Avg (30-Day) 75,182
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 763,532
  • Open Int (30-Day) 662,664
  • Expected Range 7.60 to 9.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.93 +42.50%
on 02/17/26
12.43 -32.02%
on 02/25/26
+1.52 (+21.93%)
since 02/09/26
3-Month
1.95 +333.33%
on 12/31/25
12.43 -32.02%
on 02/25/26
+6.23 (+280.63%)
since 12/09/25
52-Week
1.83 +361.75%
on 05/07/25
12.43 -32.02%
on 02/25/26
+5.45 (+181.67%)
since 03/07/25

Most Recent Stories

More News
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

CULVER CITY, Calif. , March 9, 2026 /PRNewswire/ -- ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged...

IBRX : 8.45 (-2.54%)
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

ImmunityBio, Inc. ( NASDAQ: IBRX ), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress...

IBRX : 8.45 (-2.54%)
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Study fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated...

IBRX : 8.45 (-2.54%)
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at ...

IBRX : 8.45 (-2.54%)
ImmunityBio: Q4 Earnings Snapshot

ImmunityBio: Q4 Earnings Snapshot

IBRX : 8.45 (-2.54%)
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year...

IBRX : 8.45 (-2.54%)
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom...

IBRX : 8.45 (-2.54%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised...

IBRX : 8.45 (-2.54%)
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries Dublin-based subsidiary to support ImmunityBio’s distribution...

IBRX : 8.45 (-2.54%)
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),...

IBRX : 8.45 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 9.56
2nd Resistance Point 9.18
1st Resistance Point 8.81
Last Price 8.45
1st Support Level 8.06
2nd Support Level 7.68
3rd Support Level 7.31

See More

52-Week High 12.43
Last Price 8.45
Fibonacci 61.8% 8.38
Fibonacci 50% 7.13
Fibonacci 38.2% 5.88
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar